{
    "analysis_result": {
        "judgment": "合理超适应症用药",
        "confidence": 0.85,
        "evidence_chain": {
            "drug_label": {
                "source": "西地那非说明书",
                "version": "2024版",
                "evidence": [
                    "获批适应症：原发性肺动脉高压",
                    "作用机制：通过抑制PDE5增加cGMP水平，导致肺血管平滑肌舒张"
                ]
            },
            "clinical_guidelines": {
                "source": "欧洲呼吸学会指南",
                "version": "2022版",
                "evidence": [
                    "推荐级别：IIa",
                    "证据等级：B",
                    "用于继发性肺动脉高压的治疗"
                ]
            },
            "expert_consensus": {
                "source": "中国肺纤维化诊疗专家共识",
                "version": "2024版",
                "evidence": [
                    "对于合并肺动脉高压的IPF患者可考虑使用PDE5抑制剂"
                ]
            },
            "clinical_trials": {
                "source": "临床研究",
                "evidence": [
                    {
                        "id": "NCT12345678",
                        "phase": 3,
                        "conclusion": "对继发性肺动脉高压患者有效且安全"
                    }
                ]
            },
            "mechanism_analysis": {
                "similarity_score": 0.85,
                "evidence": [
                    "与原发性肺动脉高压共享NO-cGMP信号通路",
                    "具有相似的血管舒张机制"
                ]
            }
        },
        "risk_assessment": {
            "safety_level": "可接受",
            "monitoring_suggestions": [
                "定期监测肺功能",
                "关注血压变化",
                "注意药物相互作用"
            ]
        }
    }
}
